CAR-T success rates: understanding response, remission and survival

Begin with the outcome you want to understand

For one patient, the immediate aim may be remission before another treatment. For another, it may be longer disease control or time without regular cancer-drug dosing. Ask the clinician which outcome the proposed CAR-T treatment is intended to improve in your situation.

Then identify the measure in the quoted result. Overall response usually includes partial and complete responses. Complete response uses defined disease-specific criteria. Overall survival measures whether people are alive after a stated period, whatever their response category. Keeping these labels attached to the number prevents a promising response figure from answering the wrong question.

Sources and references: [1] [2]

A deep response is assessed in a specific way

Leukemia, lymphoma and myeloma use different tests and criteria. A leukemia assessment may include marrow and measurable residual disease testing; lymphoma commonly uses imaging; myeloma follows protein markers, marrow findings and other disease features. Ask which test defines a complete response for your diagnosis.

Minimal residual disease, or MRD, testing looks for small amounts of cancer using sensitive methods. The report should state the method and its sensitivity. An MRD-negative result can provide valuable information about response depth, while the follow-up plan tracks whether that response is maintained.

Sources and references: [3] [2]

Add time to the response figure

Duration of response describes how long a response lasts among patients who responded. Progression-free survival measures time until the disease progresses or the patient dies in the group being analyzed. Overall survival measures time until death from any cause. These answer related but distinct questions.

When a report gives a median, half the group has reached the relevant event by that time. It is not a personal deadline. If the median has not been reached, ask how long patients have been followed and what proportion remains free of the event at a clearly stated time point.

Sources and references: [2]

A myeloma example shows why the labels matter

In the randomized KarMMa-3 study summarized by NCI, patients with relapsed or refractory myeloma after two to four prior lines received idecabtagene vicleucel or one of several standard regimens. The overall response rate was 71% with ide-cel and 42% with the comparison regimens; complete responses were 39% and 5%, respectively.

At a median follow-up of 30.9 months, median progression-free survival was 13.8 months with ide-cel and 4.4 months with the comparison regimens. These figures help discuss that treatment setting. For another CAR-T product, an earlier line or a different cancer, ask for the results from the matching patient group.

Sources and references: [2]

Ask who is included in the percentage

Some reports describe everyone assigned to a treatment strategy. Others focus on patients who actually received the cell infusion. This matters because a patient may become unwell, have progression or face a manufacturing problem before infusion. Both the chance of reaching treatment and the outcome after treatment belong in planning.

Ask the center to explain the journey from referral to infusion for patients like you. Useful questions include how long preparation takes, when bridging treatment is considered and what happens if the schedule changes. These details connect trial figures with the practical decision you are making.

Sources and references: [4]

Compare patients with a similar treatment history

The cancer subtype, earlier medicines, number of prior lines and current disease burden can all influence how relevant a study is. A result in patients treated at first relapse may be different from one after many previous therapies. Prior exposure to the same target also deserves attention.

Bring a treatment timeline to the discussion and ask the specialist to identify the closest evidence. If comparing products, ask whether they were tested directly against each other or against different alternatives. The answer helps the team explain why a particular option fits your situation.

Sources and references: [2] [5]

Read benefit and treatment burden together

A useful comparison includes severe side effects, infection, hospital care, blood-count recovery and the chance of needing more treatment. CAR-T can produce lasting remissions in some settings, but the preparation and recovery period can be demanding. Ask how much help you are likely to need and how the center manages complications.

Long-term monitoring includes attention to uncommon second cancers. Discuss this alongside the expected benefit for your current cancer. The question is how the whole treatment plan compares with the options available to you now, including your priorities for time at home and quality of life.

Sources and references: [1] [6]

Bring the quoted result to a Shanghai review

If a clinic, article or advertisement gives a success rate, save the source and take it to the consultation. Ask the team to name the product, disease group, treatment line and outcome behind the number. A clear explanation should connect the evidence with your own records.

EastMedGo can help prepare those records for a CAR-T eligibility review in Shanghai. Through our contact page, tell us the diagnosis, previous treatments and the figure you want clarified. We can help focus the appointment on expected benefit, alternatives and the practical steps involved.

Common questions